Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et åbent, randomiseret, multicentrisk, fase 2-studie af FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab til andenlinjebehandling af metastatisk, RAS-muteret, mikrosatellitstabil (MSS) tyktarmskræft

3. november 2026 opdateret af: Oncolytics Biotech

En åben, randomiseret, multicentrisk, fase 2-undersøgelse af FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab til andenlinjebehandling af metastatisk, RAS-muteret, mikrosatellit-stabil (MSS) tyktarmskræft

This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.

Studieoversigt

Detaljeret beskrivelse

Approximately 60 patients will be randomized 1:1 to the following study arms:

  • Arm A: FOLFIRI + bevacizumab + pelareorep
  • Arm B: FOLFIRI + bevacizumab The primary endpoint is ORR as assessed by the investigator per RECIST 1.1. OS, PFS, and assessment of the safety and tolerability of the study treatment combinations are secondary endpoints. The primary endpoint analysis will be performed after all patients have had at least one tumor assessment following initiation of study treatment or have progressed. The secondary endpoint analyses will take place at EOS.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Name: Reference Study ID Number: REO 033
  • Telefonnummer: +1 (858) 247-7829
  • E-mail: REO-033@oncolytics.com

Studiesteder

    • Alabama
      • Homewood, Alabama, Forenede Stater, 35209
    • California
      • Beverly Hills, California, Forenede Stater, 90211
        • Rekruttering
        • Clinical Research Advisors (Beverly Hills)
        • Kontakt:
      • Encino, California, Forenede Stater, 91316
        • Rekruttering
        • Clinical Research Advisors (Encino)
      • Koreatown, California, Forenede Stater, 90020
        • Rekruttering
        • Clinical Research Advisors (Korea Town)
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • Clinical Research Advisors (Downtown LA)
      • Los Angeles, California, Forenede Stater, 90048
        • Rekruttering
        • Clinical Research Advisors (West Hollywood)
      • West Covina, California, Forenede Stater, 91790
        • Rekruttering
        • Clinical Research Advisors (West Covina)
    • Florida
      • Tampa, Florida, Forenede Stater, 33612
    • Georgia
    • Idaho
      • Post Falls, Idaho, Forenede Stater, 83854
    • Illinois
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46250
        • Rekruttering
        • Community Health Network
        • Kontakt:
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48201
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Kontakt:
    • New Jersey
      • Florham Park, New Jersey, Forenede Stater, 07932
      • New Brunswick, New Jersey, Forenede Stater, 08901
        • Rekruttering
        • Rutgers Cancer Institute
        • Kontakt:
    • Ohio
      • Canton, Ohio, Forenede Stater, 44718
      • Cincinnati, Ohio, Forenede Stater, 45219
        • Rekruttering
        • University of Cincinnati Medical Center
      • Colombus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • Ohio State University
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • The University of Texas MD Anderson Cancer Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed cancer of the colon or rectum with documented metastasis
  • Measurable disease per RECIST v. 1.1
  • Not candidates for curative surgery or curative radiation
  • Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin
  • Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab
  • Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method
  • Tumor confirmed to harbor a known RAS mutation per a standard local testing method
  • ECOG performance status of 0 or 1
  • Patients must have adequate hematological, renal, and hepatic function
  • Female patients of childbearing potential must have a negative pregnancy test
  • Life expectancy of at least 6 months

Exclusion Criteria:

  • Undergone systemic chemotherapy, radiotherapy, or surgery, <4 weeks before study treatment
  • Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment
  • Prior treatment with irinotecan
  • Symptomatic brain metastases
  • Active autoimmune disease
  • Receiving immunosuppressive or myelosuppressive medications
  • Active, uncontrolled infections
  • Known HIV infection or active hepatitis B or C that requires anti-viral treatment
  • History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ
  • History of allergy or known hypersensitivity to any of the study drugs, study drug classes,
  • Uncontrolled or severe cardiac disease
  • Received any vaccine within 28 days prior to first study treatment

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A

Bevacizumab (5 mg/kg) IV infusion

Andre navne:
  • Avastin

irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion

pelareorep 4.5 x 10^10 TCID50 IV infusion

Eksperimentel: Arm B

Bevacizumab (5 mg/kg) IV infusion

Andre navne:
  • Avastin

irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall Response Rate (ORR)
Tidsramme: At week 8

Proportion of patients with complete response [CR], partial response [PR] assessed by the investigators and/or central reader according to RECIST v1.1

At week 8

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall Survival (OS) -
Tidsramme: From the date of randomization through long term follow up at two years

OS defined as the time from date of randomization to death from any cause

From the date of randomization through long term follow up at two years
Progression Free Survival (PFS)
Tidsramme: From randomization to objective progression or death from any cause, whichever occurs first, up to two years

Time from randomization to the date of investigator-determined objective progression (according to RECIST 1.1) or death from any cause, whichever occurs first.

From randomization to objective progression or death from any cause, whichever occurs first, up to two years
Disease Control Rate (DCR)
Tidsramme: From randomization to disease progression or death from any cause, whichever occurs first, up to two years

Overall DCR, defined as the number of patients with a best overall response of CR, PR, or SD according to RECIST v. 1.1

From randomization to disease progression or death from any cause, whichever occurs first, up to two years
Duration of Response (DOR)
Tidsramme: From randomization to disease progression or death from any cause, whichever occurs first, up to two years

Time from documentation of the first CR or PR to the time of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death.

From randomization to disease progression or death from any cause, whichever occurs first, up to two years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. april 2026

Primær færdiggørelse (Anslået)

30. august 2027

Studieafslutning (Anslået)

30. april 2030

Datoer for studieregistrering

Først indsendt

25. februar 2026

Først indsendt, der opfyldte QC-kriterier

25. februar 2026

Først opslået (Faktiske)

3. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner